Records containing: Primary Myelofibrosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-09-25A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
-
CLINICAL_TRIALS study record update · 2025-09-22A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
-
CLINICAL_TRIALS study record update · 2025-08-13A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study
-
CLINICAL_TRIALS study record update · 2025-07-10A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions
-
CLINICAL_TRIALS study record update · 2025-07-03Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-05-30Single Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning Matched Donor Hematopoietic Cell Transplantation With Peripheral Blood Stem Cells as Graft Source
-
CLINICAL_TRIALS study record update · 2025-05-23A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 Versus Best Available Therapy in Subjects With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)
-
CLINICAL_TRIALS study record update · 2025-04-02Microenvironment Cross-talk: Role of Extracellular Vesicles Derived From Mesenchymal Stromal Cells of Patients With Primary Myelofibrosis in Modifying Functional Activities of CD34+ Hematopoietic Progenitor Cells
-
CLINICAL_TRIALS study record update · 2025-03-30A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis
-
CLINICAL_TRIALS study record update · 2025-02-19A Study to Evaluate 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
-
CLINICAL_TRIALS study record update · 2024-12-05Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
-
CLINICAL_TRIALS study record update · 2024-11-06Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With Myelofibrosis
-
CLINICAL_TRIALS study record update · 2024-10-28A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
-
CLINICAL_TRIALS study record update · 2024-10-09A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
-
CLINICAL_TRIALS study record update · 2024-10-04A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
-
CLINICAL_TRIALS study record update · 2024-08-27Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)
-
CLINICAL_TRIALS study record update · 2024-08-23A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
-
CLINICAL_TRIALS study record update · 2024-08-12Observatoire Brestois Des Néoplasies Myéloprolifératives
-
CLINICAL_TRIALS study record update · 2024-05-29A Phase 2 Pilot Randomized Controlled Trial Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
-
CLINICAL_TRIALS study record update · 2024-05-03Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) Inhibition
-
CLINICAL_TRIALS study record update · 2024-04-17Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms: Comparison With MRI Examination
-
CLINICAL_TRIALS study record update · 2024-04-02A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
-
CLINICAL_TRIALS study record update · 2024-03-05JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
-
CLINICAL_TRIALS study record update · 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
-
CLINICAL_TRIALS study record update · 2024-02-08Observational Study Protocol REALFed - Real World Evidence of Fedratinib Effectiveness in Myelofibrosis